Healthcare
•3759 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3759)
| Company | Market Cap | Price |
|---|---|---|
|
ICUI
ICU Medical, Inc.
Infusion Systems is a major product line (Plum pumps, Medfusion/CADD integration) central to ICU Medical's revenue.
|
$3.68B |
$149.32
-1.70%
|
|
MIRM
Mirum Pharmaceuticals, Inc.
Core business includes liver disease therapeutics, with LIVMARLI and CTEXLI and acquired bile acid medications.
|
$3.67B |
$73.17
+1.96%
|
|
SWTX
SpringWorks Therapeutics, Inc.
SpringWorks specializes in oncology therapies using targeted small-molecule modalities (nirogacestat and mirdametinib).
|
$3.52B |
$46.99
|
|
NVST
Envista Holdings Corp
Envista directly manufactures dental equipment, including implants and aligners, a core product line.
|
$3.49B |
$20.98
-0.31%
|
|
LIVN
LivaNova PLC
Directly manufactures/distributes Neuromodulation Devices, including VNS Therapy and proximal hypoglossal nerve stimulation systems.
|
$3.49B |
$63.78
-0.09%
|
|
XENE
Xenon Pharmaceuticals Inc.
Xenon's lead asset XEN1101 is a selective Kv7 potassium channel opener, mapping to Ion Channel Modulators.
|
$3.43B |
$44.47
+1.21%
|
|
CGON
CG Oncology, Inc. Common stock
CG Oncology is a biotech company focused on oncology therapies, with cretostimogene grenadenorepvec representing an oncology product in late-stage development.
|
$3.42B |
$44.84
+0.01%
|
|
TARS
Tarsus Pharmaceuticals, Inc.
XDEMVY is an FDA-approved ophthalmic drug and core commercial product for Demodex blepharitis.
|
$3.40B |
$80.53
+0.03%
|
|
ATEC
Alphatec Holdings, Inc.
Alphatec's primary business is spine/orthopedic implants and devices.
|
$3.34B |
$22.61
+3.55%
|
|
IPGP
IPG Photonics Corporation
IPG markets medical laser systems including thulium lasers for urology, fitting Medical Devices & Biometrics.
|
$3.31B |
$78.60
+1.28%
|
|
AMED
Amedisys, Inc.
Direct provision of Home Health and Hospice services across multiple centers.
|
$3.31B |
$100.99
|
|
UUUU
Energy Fuels Inc.
Radium/radioisotope recovery plans for targeted alpha therapy isotopes (radiopharmaceuticals).
|
$3.31B |
$14.38
+0.10%
|
|
IRON
Disc Medicine, Inc.
Disc Medicine concentrates on rare hematologic diseases (e.g., EPP, Diamond-Blackfan anemia) by targeting iron and heme pathways, with a pipeline centered on rare-disease indications.
|
$3.26B |
$93.73
+1.30%
|
|
RARE
Ultragenyx Pharmaceutical Inc.
Ultragenyx is a rare-disease focused biotech company with approved therapies and a pipeline centered on ultra-rare diseases.
|
$3.25B |
$33.75
+0.67%
|
|
TVTX
Travere Therapeutics, Inc.
Lead product FILSPARI (sparsentan) is an oral small molecule therapeutic for IgA nephropathy, representing the core commercial and product-focused program.
|
$3.23B |
$36.27
+0.72%
|
|
KNSA
Kiniksa Pharmaceuticals, Ltd.
Kiniksa's core clinical focus centers on immunology therapeutics, driven by ARCALYST and its inflammatory disease pipeline.
|
$3.15B |
$42.53
-0.42%
|
|
IDYA
IDEAYA Biosciences, Inc.
IDEAYA is a biotechnology company focused on precision oncology therapies (synthetic lethality and ADCs).
|
$3.14B |
$35.89
+0.03%
|
|
FOLD
Amicus Therapeutics, Inc.
Amicus Therapeutics’s marketed products address rare genetic diseases (Fabry and Pompe) and its pipeline includes a rare-kidney disease program (DMX-200 for FSGS), placing it in Biotech - Rare Diseases.
|
$3.09B |
$10.02
+1.47%
|
|
DYN
Dyne Therapeutics, Inc.
Dyne's FORCE platform is a drug delivery platform enabling targeted payload delivery to muscle and CNS, making it a core product category.
|
$3.01B |
$21.17
|
|
ADPT
Adaptive Biotechnologies Corporation
ADPT directly provides clonoSEQ MRD diagnostic testing and related laboratory services.
|
$3.00B |
$19.73
+0.03%
|
|
PRVA
Privia Health Group, Inc.
Privia provides physician enablement, MSO and value-based care services, i.e., Healthcare Services & Facilities.
|
$3.00B |
$24.48
-0.35%
|
|
SXI
Standex International Corporation
Medical devices & biometrics/public healthcare equipment segment exposure.
|
$2.94B |
$243.50
+0.49%
|
|
PBH
Prestige Consumer Healthcare Inc.
Clear Eyes is an ophthalmic over-the-counter product, fitting Ophthalmic Drugs.
|
$2.93B |
$59.56
+0.93%
|
|
MLYS
Mineralys Therapeutics, Inc.
The company is pursuing a cardiovascular hypertension therapy, placing Mineralys under the Cardiovascular Drugs category.
|
$2.87B |
$43.37
+2.76%
|
|
CPRX
Catalyst Pharmaceuticals, Inc.
CPRX directly develops and sells oral small molecule therapeutics (FIRDAPSE, AGAMREE, FYCOMPA).
|
$2.87B |
$23.43
-0.68%
|
|
TNET
TriNet Group, Inc.
Health Insurance as TriNet provides employee group health benefits to client workforces.
|
$2.84B |
$58.52
-0.51%
|
|
DNLI
Denali Therapeutics Inc.
DNL310 and DNL126 are recombinant enzymes delivered via Denali's TransportVehicle platform, representing its core product categories.
|
$2.84B |
$19.40
|
|
NUVB
Nuvation Bio Inc.
Core oncology focus with IBTROZI and safusidenib as oncology therapies, fitting Biotech - Oncology.
|
$2.74B |
$8.02
+1.78%
|
|
LQDA
Liquidia Corporation
Liquidia's YUTREPIA is a PRINT-enabled inhaled treprostinil, a drug-delivery platform that enables high-dose, deep-lung delivery and differentiated pharmacokinetics.
|
$2.73B |
$31.72
|
|
APLS
Apellis Pharmaceuticals, Inc.
SYFOVRE is an ophthalmic drug (intravitreal) approved for geographic atrophy, representing a direct product Apellis sells.
|
$2.73B |
$21.57
+2.74%
|
|
RCUS
Arcus Biosciences, Inc.
Arcus operates in oncology with innovative IO therapies (HIF-2α inhibitor casdatifan; TIGIT antibody domvanalimab; CD73 inhibitor quemliclustat) making it a Biotech - Oncology company.
|
$2.72B |
$25.57
+5.29%
|
|
EWTX
Edgewise Therapeutics, Inc.
Edgewise's lead programs sevasemten and EDG-7500 are orally administered small-molecule therapeutics, i.e., an oral small molecule therapeutics platform.
|
$2.69B |
$25.51
-0.04%
|
|
CON
Concentra Group Holdings Parent, Inc.
The business provides diagnostic testing via its clinics, aligning with laboratory testing and diagnostic service capabilities.
|
$2.67B |
$20.86
-1.39%
|
Showing page 9 of 38 (3759 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
